Search results for "onset"

showing 10 items of 496 documents

Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission.…

2019

Abstract To assess the effectiveness of the treatment with high dosage of corticosteroids (CCSs), as first-line therapy, in inducing remission in naïve Adult-onset Still's disease (AOSD) patients compared with low dosage of CCSs, after 6 months. To further evaluate the rate of patients maintaining the remission and the rate of CCSs discontinuation, after additional 12 months of follow-up. A retrospective evaluation of patients prospectively followed was designed to compare the rate of clinical remission in naïve AOSD patients treated with high dosages of CCSs (0.8–1 mg/kg/day of prednisone-equivalent) or low dosage of CCSs (0.2–0.3 mg/kg/day of prednisone-equivalent), after 6 months. An add…

Adult-OnsetMalePediatricsAdult-onset Still's diseaseDiseaseAdrenal Cortex Hormonecorticosteroids0302 clinical medicinemonocyclic patternAdrenal Cortex HormonesRetrospective StudieMedicine030212 general & internal medicineProspective StudiesProspective cohort studyRemission InductionDisease ManagementGeneral MedicineMiddle AgedTreatment OutcomeHigh dosage030220 oncology & carcinogenesisFemaleDrugStill's Disease Adult-OnsetResearch ArticleHumanAdultcorticosteroidmedicine.medical_specialtyLow dosageObservational StudyAdult-onset Still's diseaseFollow-Up StudieDose-Response Relationship03 medical and health sciencesremissionAdult-onset Still's disease; corticosteroids; first-line therapy; monocyclic pattern; remission; Adrenal Cortex Hormones; Adult; Disease Management; Dose-Response Relationship Drug; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Remission Induction; Retrospective Studies; Still's Disease Adult-Onset; Treatment Outcomefirst-line therapyHumansRetrospective StudiesDose-Response Relationship Drugbusiness.industry6900Retrospective cohort studyStill's DiseaseFirst line treatmentSettore MED/16 - ReumatologiaProspective StudieMethotrexateObservational studybusinessFollow-Up Studies
researchProduct

Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial.

2014

OBJECTIVE To evaluate safety and efficacy of DiaPep277 in preserving β-cell function in type 1 diabetic patients. RESEARCH DESIGN AND METHODS DIA-AID 1 is a multinational, phase 3, balanced-randomized, double-blind, placebo-controlled, parallel-group clinical study. Newly diagnosed patients (N = 457, aged 16–45 years) were randomized to subcutaneous injections of DiaPep277 or placebo quarterly for 2 years. The primary efficacy end point was the change from baseline in the area under the glucagon-stimulated C-peptide curve. Secondary end points were the change from baseline in mixed-meal stimulated C-peptide secretion and in fasting C-peptide and achieving target HbA1c ≤7% (≤53 mmol/mol). P…

Advanced and Specialized NursingResearch designType 1 diabetesmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInsulinmedicine.medical_treatmentPlacebomedicine.diseaseGastroenterologySurgeryDouble blindType 1 diabetesInternal medicineDiabetes mellitusInternal MedicinemedicineRecent onsetbusinessGlycemic
researchProduct

Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate

2017

Key Clinical Message Prompt ophthalmology evaluation and immediate imatinib suspension should be suggested at any time of tyrosine kinase inhibitor therapy in patients with visual deficit, as it may be a clinical manifestation of optic disk edema, and suspension may help in prompt recovery.

Adverse event0301 basic medicinegenetic structuresmedicine.drug_classOptic Disk EdemaLate onsetCase ReportClinical manifestationCase ReportsTyrosine-kinase inhibitor03 medical and health sciences0302 clinical medicinechronic myeloid leukemiatyrosine kinase inhibitorsmedicineIn patientAdverse effectbusiness.industryoptic disk edemaImatinibGeneral Medicineeye diseases030104 developmental biologyImatinib mesylateimatiniboptic nerve edemaAnesthesiaAdverse events030221 ophthalmology & optometrybusinessmedicine.drugClinical Case Reports
researchProduct

Childhood Maltreatment, Educational Attainment, and IQ: Findings From a Multicentric Case-control Study of First-episode Psychosis (EU-GEI).

2022

[Background and hypothesis] Evidence suggests that childhood maltreatment (ie, childhood abuse and childhood neglect) affects educational attainment and cognition. However, the association between childhood maltreatment and Intelligence Quotient (IQ) seems stronger among controls compared to people with psychosis. We hypothesised that: the association between childhood maltreatment and poor cognition would be stronger among community controls than among people with first-episode of psychosis (FEP); compared to abuse, neglect would show stronger associations with educational attainment and cognition; the association between childhood maltreatment and IQ would be partially accounted for by ot…

Affective Disorders PsychoticIntelligence TestsSTRESSchildhood abuseBIPOLAR DISORDERASSOCIATIONschizophreniaPsychiatry and Mental healthPsychotic DisordersIQADVERSITIESCase-Control StudiesONSETRELIABILITYPHYSICAL ABUSEHumanschildhood neglectpsychosisChild AbuseVALIDITYChildRegular ArticlesTRAUMA
researchProduct

Obesity and new-onset atrial fibrillation in acute myocardial infarction: a gender specific risk factor

2014

Aged 80 and overMaleSex Characteristicsmedicine.medical_specialtybusiness.industryMyocardial InfarctionSpecific riskAtrial fibrillationMiddle Agedmedicine.diseaseObesityNew onset atrial fibrillationRisk FactorsInternal medicineAtrial FibrillationmedicineCardiologyHumansFemaleObesityMyocardial infarctionCardiology and Cardiovascular MedicinebusinessAgedInternational Journal of Cardiology
researchProduct

Brain aging and late-onset Alzheimer's disease: many open questions.

2012

ABSTRACTDespite decades of research in the field of Alzheimer's disease (AD), a real understanding of its molecular pathophysiology and treatments relevant to the day-to-day lives of patients remain out of reach. Research has, with good reason, focused on certain key pathways and potential mechanisms, but sometimes this has been at the expense of work on other theories, which may be slowing down progress in this field. Interesting theories at present include oxidative stress and caloric restriction. Work on the Aβ cascade should continue but with a shift in focus to its intracellular effects and an awareness that additional pathogenetic factors and processes must be involved – most importan…

AgingHyperphosphorylationLate onsettau ProteinsDiseaseEpigenesis GeneticAmyloid beta-Protein PrecursorAlzheimer DiseaseIntervention (counseling)MedicineDementiaAnimalsHumansEpigeneticsCaloric Restrictionbusiness.industryNeurodegenerationBrainmedicine.diseasePsychiatry and Mental healthClinical PsychologyOxidative StressGeriatrics and GerontologyAlzheimer's diseasebusinessGerontologyNeuroscienceInternational psychogeriatrics
researchProduct

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Perturbation of metabolic pathways mediates the association of air pollutants with asthma and cardiovascular diseases.

2018

Background: Epidemiologic evidence indicates common risk factors, including air pollution exposure, for respiratory and cardiovascular diseases, suggesting the involvement of common altered molecular pathways. Objectives: The goal was to find intermediate metabolites or metabolic pathways that could be associated with both air pollutants and health outcomes (“meeting-in-the-middle”), thus shedding light on mechanisms and reinforcing causality. Methods: We applied a statistical approach named ‘meet-in-the-middle’ to untargeted metabolomics in two independent case-control studies nested in cohorts on adult-onset asthma (AOA) and cardio-cerebrovascular diseases (CCVD). We compared the results …

Air pollution Untargeted metabolomics Metabolic pathways Adult-onset asthma Cardio-cerebrovascular diseases0301 basic medicineChronic exposureAdultAir pollution exposureAir pollutionAir pollution010501 environmental sciencesmedicine.disease_cause01 natural sciencesSettore MED/01 - Statistica Medica03 medical and health sciencesAir pollutantsMD MultidisciplinarymedicineHumans0105 earth and related environmental sciencesGeneral Environmental ScienceAsthmaCardio-cerebrovascular diseasesAir PollutantsUntargeted metabolomicsOdds ratioEnvironmental Exposuremedicine.diseaseAsthmaMetabolic pathway030104 developmental biologyUntargeted metabolomicsMetabolic pathwaysCardiovascular DiseasesCase-Control StudiesImmunologyEXPOsOMICS ConsortiumEnvironmental SciencesMetabolic Networks and PathwaysAdult-onset asthmaEnvironment international
researchProduct

Metabolic impact of adult-onset, isolated, growth hormone deficiency (AOiGHD) due to destruction of pituitary somatotropes.

2011

Growth hormone (GH) inhibits fat accumulation and promotes protein accretion, therefore the fall in GH observed with weight gain and normal aging may contribute to metabolic dysfunction. To directly test this hypothesis a novel mouse model of adult onset-isolated GH deficiency (AOiGHD) was generated by cross breeding rat GH promoter-driven Cre recombinase mice (Cre) with inducible diphtheria toxin receptor mice (iDTR) and treating adult Cre(+/-), iDTR(+/-) offspring with DT to selectively destroy the somatotrope population of the anterior pituitary gland, leading to a reduction in circulating GH and IGF-I levels. DT-treated Cre(-/-), iDTR(+/-) mice were used as GH-intact controls. AOiGHD im…

Anatomy and PhysiologyMousemedicine.medical_treatmentgh deficiencyMiceEndocrinology0302 clinical medicinefactor-iInsulinglucoseAge of OnsetInsulin-Like Growth Factor I2. Zero hunger0303 health scienceseducation.field_of_studyMultidisciplinarypancreatic beta-cellQRAnimal ModelsGHreceptor genehypothalamic expressionmedicine.anatomical_structureCarbohydrate MetabolismIntercellular Signaling Peptides and ProteinsMedicineincreased insulin sensitivityResearch ArticleHeparin-binding EGF-like Growth Factormedicine.medical_specialtymicediet-induced obesityDisfunción metabólicaSomatotropic cellSciencePopulationEndocrine System030209 endocrinology & metabolismBiologyCarbohydrate metabolismGrowth hormone deficiency03 medical and health sciencesModel OrganismsInsulin resistanceAnterior pituitaryreplacement therapyPituitary Gland AnteriorGrowth FactorsInternal medicinemedicineAnimalsObesityeducationBiologyNutrition030304 developmental biologyDiabetic EndocrinologyEndocrine PhysiologyInsulinDiabetes Mellitus Type 2Metabolyc disfunctionmedicine.diseaseHormonesMice Mutant StrainsSomatotrophsProlactinDietRatsDisease Models AnimalEndocrinologyPituitaryGrowth HormoneInsulin ResistanceEnergy IntakeEnergy MetabolismGHDPLoS ONE
researchProduct

Poor Esophageal Motility: A Tailored Approach?

2014

New onset dysphagia following antireflux surgery is among the most undesirable side effects of an otherwise excellent therapy. While its cause is multifactorial, insufficient circular muscle strength of the esophageal body, not powerful enough to force the bolus through the distal neo-high pressure zone, can be a component of the pathophysiology. The relative merits of “tailoring” the degree of fundoplication based upon esophageal body motility and/or other clinical features have been debated for decades. Herein we discuss the rationale for a tailored approach, its pros and cons and review data published to date available to guide the clinician in individual patient decision-making.

Antireflux surgerymedicine.medical_specialtyTailored approachbusiness.industryEsophageal bodyDysphagiaNew onsetPoor esophageal motilityCircular musclemedicinemedicine.symptomIntensive care medicinebusinessPartial fundoplication
researchProduct